Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of ...

Most people with multiple myeloma are diagnosed in their 60s, 70s or 80s. “Myeloma is predominantly a disease of aging, so the older you get, the more likely you are to get it,” Mohyuddin said.

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Here’s my take on myeloma-related studies that I’m excited about now and in the year ahead, with a focus on smoldering multiple myeloma (SMM), newly diagnosed disease, and first relapse. A key ...

An analysis of IBM rates for multiple myeloma from 2000 to 2021 found that significant disparities persist in myeloma outcomes based on household income and geographic location. 1 Drawing on SEER ...

Meanwhile, Pfizer’s bispecific antibody for multiple myeloma is Elrexfio, which targets BCMA on cancer cells and CD38 on T cells. Elrexfio is administered every two weeks after step-up dosing.

Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are “hideously expensive,” Dr. June said, costing more than $100,000 a year.

We conducted a phase 1b–2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. In phase 1, we investigated five dose levels in a dose-escalation study.